Search
PA-1050040
go.drugbank.com/drugs/DB06039ExperimentalPA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.
Cholesteryl chloride
go.drugbank.com/drugs/DB14045ExperimentalCholesteryl chloride, also known as 3-chlorocholest-5-ene, is an organochloride derivative of cholesterol. It is presented as a liquid crystal that forms clockwise liquid crystals.
Synonyms: 3-Chlorocholest-5-eneLuLym-T
go.drugbank.com/drugs/DB17405ExperimentalLuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.
TZP-102
go.drugbank.com/drugs/DB16129InvestigationalTZP-102 is under investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis).
Benzbromarone
go.drugbank.com/drugs/DB12319ApprovedWithdrawnBenzbromarone has been used in trials studying the basic science and treatment of Heart Failure, Hyperuricemia, Chronic Kidney Disease, Abnormal Renal Function, and Gout and Asymptomatic Hyperuricemia.
Fluindione
go.drugbank.com/drugs/DB13136ApprovedWithdrawnFluindione is under investigation for the treatment of Venous Thrombosis, Pulmonary Embolism, Permanent Atrial Fibrillation, and Anticoagulating Treatment on a Duration at Least 12-month-old Superior.
Padoprazan
go.drugbank.com/drugs/DB21689ExperimentalThe usage of the INN stem '-prazan' in the name indicates that Padoprazan is a proton pump inhibitor, not dependent on acid activation. Padoprazan has a monoisotopic molecular weight of 405.12 Da.
HNM01
go.drugbank.com/drugs/DB06531ExperimentalThe drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor.
VPM4001
go.drugbank.com/drugs/DB05089ExperimentalVPM4001 is an allogeneic vaccine for treatment of prostate carcinoma.
Reglitazar
go.drugbank.com/drugs/DB04971ExperimentalReglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.